What is the purpose of this trial?
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Start Date: 05/21/2019
End Date: 06/01/2021
Last Updated: 05/22/2019
Study HIC#: 2000024410